Plain-English translation of NCT05786924 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called (also known as BDTX-4933) to see if it can help treat advanced cancers that have specific genetic mutations. The medication will be given by mouth, either alone or combined with other cancer treatments depending on your cancer type. Researchers want to find the safest and most effective dose, and to understand how well this treatment works for different types of advanced cancer.
Many advanced cancers are driven by mutations in genes called KRAS and BRAF, and current treatments don't work well enough for all patients. This trial exists to find out whether this new medication—which targets these specific genetic mutations—can help patients whose cancers have stopped responding to other therapies or who have limited treatment options.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth every day in 28-day treatment cycles. Depending on which part of the trial you join, you may take the medication alone or combined with other chemotherapy drugs. You will have regular visits with the research team for blood tests, scans, and check-ups to monitor how you're responding and watch for any side effects. You will continue treatment as long as the cancer is not growing, you are tolerating the medication well, and you wish to remain in the trial.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
United States